New diabetes shot shows promise in early safety trial
NCT ID NCT06439056
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 29 times
Summary
This early-phase study tested a new long-acting injection called NEX-22A in 12 adults with type 2 diabetes. The main goal was to see how the drug moves through the body and whether it is safe. Participants received a single dose, and researchers measured drug levels and side effects over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Profil
Neuss, 41460, Germany
Conditions
Explore the condition pages connected to this study.